A 28-year-old woman attends the STI clinic with a 5-day history of dysuria, purulent urethral discharge, and lower abdominal pain. She reports a new sexual partner 2 weeks ago. On examination, there is cervical erythema and mucopurulent endocervical discharge. Urinalysis shows pyuria. A Gram stain of the urethral discharge reveals gram-negative intracellular diplococci within neutrophils. Which of the following is the most appropriate first-line treatment?

Explanation

## Clinical Diagnosis **Key Point:** This patient has uncomplicated urogenital gonorrhea caused by *Neisseria gonorrhoeae*, confirmed by gram-negative intracellular diplococci in neutrophils (pathognomonic finding). ## Diagnostic Features of *N. gonorrhoeae* | Feature | Finding | |---------|----------| | Gram stain | Gram-negative diplococci (kidney bean-shaped) | | Location | Intracellular within PMNs | | Culture | Oxidase-positive, ferments glucose only | | Nucleic acid test | Gold standard for diagnosis | ## Treatment Algorithm ```mermaid flowchart TD A[Uncomplicated Urogenital Gonorrhea]:::outcome --> B{Resistance Pattern?}:::decision B -->|Susceptible| C[Ceftriaxone 250 mg IM]:::action B -->|Fluoroquinolone-resistant| C C --> D[+ Azithromycin 1 g oral]:::action D --> E[Covers co-infection with Chlamydia]:::outcome F[Penicillin/Tetracycline]:::urgent --> G[NO LONGER USED]:::urgent H[Fluoroquinolones]:::urgent --> I[Resistance >50% globally]:::urgent ``` ## Current First-Line Therapy (WHO/CDC 2023) **High-Yield:** Ceftriaxone 250 mg IM single dose + azithromycin 1 g oral single dose is the recommended regimen because: 1. **Ceftriaxone:** Highly effective against *N. gonorrhoeae* with minimal resistance (<1%) 2. **Azithromycin:** Covers concurrent *Chlamydia trachomatis* (present in 20–40% of gonorrhea cases) 3. **Single-dose regimen:** Improves compliance and reduces treatment failure 4. **Avoids monotherapy:** Prevents emergence of resistance **Clinical Pearl:** Dual therapy with ceftriaxone + azithromycin is essential because: - ~30% of gonorrhea patients have concurrent chlamydial infection - Azithromycin provides coverage even if chlamydia is not detected - Monotherapy with cephalosporin alone is inadequate **Mnemonic:** **CAG** = Cephalosporin + Azithromycin for Gonorrhea (dual therapy prevents resistance and covers coinfection). ## Why Other Agents Are Obsolete | Agent | Reason for Discontinuation | |-------|----------------------------| | Penicillin G | >50% resistance globally; no longer used | | Tetracycline | High resistance rates; not recommended | | Fluoroquinolones | >50% resistance in many regions; WHO no longer recommends | **Warning:** Fluoroquinolone monotherapy is no longer recommended due to widespread resistance. Penicillin and tetracyclines should never be used for gonorrhea.